PCSK9 inhibitors (PCSK9i) clearly demonstrate LDL-C lowering and is hugely beneficial in patients with familial hypercholesterolemia and for secondary prevention of acute cardiovascular events in high-risk patients with atherosclerotic cardiovascular disease [3–5]. Here, PCSK9 is linked to familial hypercholesterolemia.